Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sunnybrook Health Sciences Centre
Primary Endpoints:
* Acute gastrointestinal (GI) and genitourinary (GU) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 toxicities
Secondary Endpoints:
* Late GI and GU Radiation Therapy Oncology Group (RTOG) toxicities
* Biochemical disease-free survival
* Biopsy positive rate at 3 years
* Quality of life using the Expanded Prostate Cancer Index Composite (EPIC) questionnaire
* Develop a biobank of DNA and serum extracted from blood and urine to analyze and develop new biomarkers for prostate cancer progression or susceptibility to severe toxicity
high risk prostate cancer, defined as at least one of: clinical stage T3, or gleason score 8-10, or PSA \> 20ng/mL
You may not be if
prior pelvic radiotherapy
anticoagulation medication (if unsafe to discontinue for gold seed insertion)
diagnosis of bleeding diathesis
pelvic girth \> 40cm (to ensure visibility of gold seeds on electronic portal imaging)
large prostate (\> 90cm3) on imaging
severe lower urinary tract symptoms (International Prostate Symptom Score \>19 or nocturia \> 3)
No evidence of castrate resistance (defined as PSA \< 3ng/mL while testosterone is \< 0.7nmol/L). Patients could have been on combined androgen blockade but are excluded if this was started due to PSA progression
